Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

Nature Reviews Immunology

Volumn 4, Issue 5, 2004, Pages 336-347

  Chen, Lieping ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; H1 ANTIGEN; PD1 PROTEIN; PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL SURFACE; CELLULAR IMMUNITY; DENDRITIC CELL; HOMEOSTASIS; LYMPHOCYTE HOMEOSTASIS; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 2442585121     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1349     Document Type: Review

References (97)

1. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2001).
2. Chen, L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 19, 27-30 (1998).
3. Croft, M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature Rev. Immunol. 3, 609-620 (2003).
4. Salomon, B. & Bluestone, J. A. Complexities of CD28/B7: CTLA-4 co-stimulatory pathway in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
5. Baxter, A. G. & Hodgkin, P. D. Activation rules: the two-signal theories of immune activation. Nature Rev. Immunol. 2, 439-446 (2002).
6. Pardoll, D. Dose the immune system see tumors as foreign or self? Annu. Rev. Immune. 21, 807-839 (2003).
7. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
8. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 932-933 (1995). References 7 and 8 show that cytotoxic T lymphocyte antigen 4 (CTLA4) is crucial for the control of autoimmunity, because lack of CTLA4 by gene targeting induces lymphoproliferative diseases and organ destruction in the fetus.
9. Mandelbrot, D. A., McAdam, A. J. & Sharpe, A. H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen (CTLA-4). J. Exp. Med. 189, 435-440 (1999).
10. Chambers, C.A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
11. Sugita, S. & Streilein, J. W. Iris pigment epithelium expressing CD86 (B7-2) directly suppresses T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 198, 161-171 (2003).
12. Lohr, J., Knoechel, B., Jiang, S., Sharpe, A. H. & Abbas, A. K. The inhibitory function of B7 co-stimulators in T cell responses to foreign and self-antigens. Nature Immunol. 4, 664-669 (2003).
13. Taylor, P. A. et al. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via R-T interactions. J. Immunol. 172, 34-39 (2004).
14. Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. & Sharpe, A. CTLA-4 regulates induction of energy in vivo. Immunity 14, 145-155 (2001).
15. Perez, V. L. et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6, 411-417 (1997).
16. + T cell- and IL-2-dependent mechanism. Immunity 11, 483-493 (1999).
17. Sotomayor E. M., Borrello, I., Tubb, E., Allison, J. P. & Levitsky, H. I. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl Acad. Sci. USA 98, 11476-11481 (1999).
18. + T cells. J. Exp. Med. 188, 1849-1857 (1998).
19. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 194, 629-644 (2001).
20. Egen J. G. & Allison, J. P. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse in regulated by TCR signal strength. Immunity 16, 23-35 (2002).
21. Darlington, P. J. et al. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J. Exp. Med. 195, 1337-1347 (2002).
22. Schwartz, J. C., Zhang X., Nathenson, S. G. & Almo, S. C. Structural mechanisms of co-stimulation. Nature Immunol. 3, 427-434 (2002).
23. Lee, K. M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263-2266 (1998).
24. Chikuma, S., Imboden, J. B. & Bluestone, J. A. Negative regulation of cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 197, 129-135 (2003).
25. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431-440 (2000).
26. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
27. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
28. Abrams, J. R. et al. CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103, 1243-1252 (1999). The first clinical evidence that CTLA4-immunoglobulin fusion protein is effective for the treatment of patients with advanced psoriasis vulgaris.
29. Abrams, J. R. et al. Blockade of T lymphocyte co-stimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192, 681-694 (2000).
30. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
31. Grohmann, U. et al. CTLA-4-Ig regulates trytophan catabolism in vivo. Nature Immunol. 3, 1097-1101 (2002).
32. Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nature Immunol. 4, 1206-1212 (2003). References 31 and 32 describe a new reverse signalling mechanism for CTLA4 in the suppression of immune responses.
33. Mellor, A. L. & Munn, D. H. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation? Immunol. Today 20, 469-473 (1999).
34. Fallarino, F. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077 (2002).
35. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992.)
36. Agata Y. et al. Expression of the PD-1 on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).
37. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo. T. Development of lupos-like autoimmune disease by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999). This is the first study showing the development of systemic autoimmune diseases in programmed cell death 1 (Pd1)-knockout mice.
38. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
39. Okazaki, T. et al. Autoantibodies against cardiac troponin 1 are responsible for dilated cardiomyopathy in PD-1 deficient mice. Nature Med. 9, 1477-1483 (2003).
40. Ansari, M. J. et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 196, 63-69
41. Salama, A. D. et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 196, 71-78 (2003).
42. Tsushima, F. et al. Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur. J. Immunol 33, 2773-2782 (2003).
43. Blazar, B. R. et al. Blockade of programmed death-1 engagement accelerate graft-verus-host disease lathality by an IFN-γ-dependent mechanism. J. Immunol. 71, 1272-1277 (2003).
44. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T. & Honjo, T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 196, 39-50 (2003).
45. Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M. & Honjo, T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23, 704-706 (1994).
46. Finger, L. R. et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in T cell progenitors. Gene 197, 177-187 (1997).
47. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl Acad. Sci. USA 96, 13866-13871 (2001).
48. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2, 261-268 (2001).
49. Blank, C. et al. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double negative TCR-transgenic T cells. J. Immunol. 171, 4574-4581 (2003).
50. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by novel B7 family member leads to negative regulation lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
51. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulate T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365-1369 (1999).
52. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8, 793-800 (2002). The study demonstrated broad expression of B7-H1 by human cancers and shows that tumour-associated B7-H1 could prevent tumour immunity by inducing apoptosis of effector. T cells in vitro and in vivo. This paper also indicates that B7-H1 has an additional receptor other than PD1.
53. Tamura, H. et al. B7-H1 co-stimulation preferentially enhances CD28-independent T-helper cell function. Blood 97, 1809-1818 (2001).
54. Yamazaki, T. et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169, 5538-5545 (2002).
55. Mazanet M. M. & Hughes, C. C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169, 3581-3588 (2002).
56. Petroff, M. G., Chen, L., Phillips, T. A. & Hunt, J. S. B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta 23 (Suppl A), S95-S101 (2002).
57. Trabattoni, D. et al. B7-H1 is upregulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101, 2514-2520 (2003).
58. Petroff, M. G. et al. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol. Reprod. 68, 1496-1504 (2003).
59. Selenko-Gebauer, N. et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 170, 3637-3644 (2003).
60. Cao, Y. et al. Karatinocytes induce local tolerance to skin graft by active interleukin-10-secreting T cells in the context of co-stimulation molecule B7-H1. Transplantation 75, 1390-1396 (2003).
61. Ishida, M. et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84, 57-62 (2002).
62. Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257-1266 (2003).
63. Tseng, S. Y. et al. B7-DC, a new dendritic cell molecule with potent co-stimulatory properties for T cells. J. Exp. Med. 193, 839-848 (2001).
64. + T cells independent of the PD-1 receptor. J. Exp. Med. 196, 31-38 (2003).
65. H2 cells. Proc. Natl Acad. Sci. USA 100, 5336-5341 (2003).
66. Kanal, T. et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J. Immunol. 171, 4156-4163 (2003).
67. Subudhi, S. K. et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J. Clin. Invest. 113, 694-700 (2004).
68. Liu, X. et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med. 197, 1721-1730 (2003).
69. Wang, S. et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple most co-stimulatory function from PD-1 interaction. J. Exp. Med. 197, 1083-1091 (2003).
70. Dong, H. et al. Co-stimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J. Clin. Invest. 111, 363-370 (2003).
71. Nguyen, L. T. et al. Crosslinking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J. Exp. Med. 196, 1393-1398 (2002).
72. Radhakrishnan, S. et al. Naturally occurring human IgM antibody that binds B7 DC and potentiates T cell stimulation by dendritic cells. J. Immunol. 170, 1830-1838 (2003).
73. Wick, M. J., Leithauser, F. & Reimann, J. The hepatic immune system. Crit. Rev. Immunol. 22, 47-103 (2002).
74. Crispe, I. N. Hepatic T cells and liver tolerance. Nature Rev. Immunol. 3, 51-62 (2003).
75. + T lymphocytes. Immunity 20, 327-336 (2004).
76. Sica, G. L. et al. B7-H4, a molecule of the B7 family, negative regulates T cell immunity. Immunity 16, 849-861 (2000.)
77. Prasad, D. V., Richards, S., Mai, X. M. & Dong, C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18, 863-873 (2003).
78. Zang, X., Loke, P., Kim, J., Murphy, K., Waitz, R. & Allison, J. P. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl Acad. Sci. USA 100, 10388-10392 (2003). References 76-78 Identity 76-78 Identity a new B7 homologue with suppressive function in vivo (references 76 and 77) and in vitro.
79. Choi, I. H. et al. Genomic organization and expression analysis of B7-H4: an immune inhibitory molecule of the B7 family. J. Immunol. 171, 4650-4654 (2003).
80. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunol. 4, 670-679 (2003). This study reports the cloning of B and T lymphocyte attenuator (BTLA) and shows that Btla-knockout mica have enhanced T-cell responses. It also claims that BTLA is a receptor for B7-H4.
81. Chapoval, A. I. et al. B7-H3: a co-stimulatory molecule for T cell activation and IFN-γ production. Nature Immunol. 2, 269-274 (2001).
82. Sun, M. et al. Characterization of mouse and human B7-H3 gene. J. Immunol. 168, 8294-6297 (2002).
83. Chapoval, A. I. & Chen, L. in The B7-CD28 Family Molecules (ed. L. Chen) 91-99 (Kluwer Academic, Plenum Publishers, New York, 2003).
84. Suh, W. K. et al. The B7 family B7-H3 preferentially downregulates T helper type 1-mediated immune responses. Nature Immunol. 4, 899-906 (2003).
85. Ling, V. et al. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 82, 365-377 (2003).
86. Steinberger, P. et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol. 172, 2352-2359 (2004).
87. Hodl, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712-4717 (2003).
88. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003). References 87 and 88 show that infusion of humanized CTLA4-specific antagonist monoclonal antibody induces clinical responses in advanced stages of melanoma accompanied by marked self-reactivity.
89. Wintterie, S. et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63, 7462-7467 (2003).
90. Strome, S. E. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63, 6501-6505 (2003).
91. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
92. Dong, H. & Chen, L. B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 81, 281-287 (2003).
93. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9, 562-567 (2003). This paper reports that dendritic cells (DCs) isolated from human ovarian cancers have upregulated expression of B7-H1, which suppression T-cell responses. Blockade of DC-associated B7-H1 by specific monoclonal antibody enhances tumour immunity.
94. Ozkaynak, E. et al. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169, 6546-6553 (2002).
95. Gao, W., Demirci, G., Strom, T. B. & Li, X. C. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term isle allograft survival. Transplantation 76, 994-999 (2003).
96. Wiendl, H. et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential; a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 17, 1892-1894 (2003).
97. Rudd, C. E. & Schneider, H. Unifying concepts in CD28, ICOS and CTLA-4 co-receptor signaling. Nature Rev. Immunol. 3, 544-656 (2003).